



IPOPI 5TH REGIONAL ASIAN PID MEETING

24-25 MARCH 2024
TOKYO, JAPAN

an **IPOPI** event

COLLABORATION



SUPPORTED BY



WELCOME TO APSID/IPOPI JOINT SESSION

PID Life Odyssey –
The Patient Journey



IPOPI
5TH REGIONAL
ASIAN PID MEETING
24-25 MARCH 2024
TOKYO, JAPAN
an IPOPI event

COLLABORATION



SUPPORTED BY



IPOPI.ORG



WI-FI

User: xxx

Password: xxx



IPOPI
5TH REGIONAL
ASIAN PID MEETING
24-25 MARCH 2024
TOKYO, JAPAN
an IPOPI event

COLLABORATION



SUPPORTED BY



IPOPI.ORG


Live Translation

Step 1



Scan QR Code or Go To:
<https://attend.wordly.ai/join/KPYA-6720>

Step 2

A screenshot of the Wordly app interface. At the top is the 'wordly' logo in blue. Below it is the text 'AI-POWERED INTERPRETATION' in pink. There are two input fields: 'Choose language *' with 'English (US)' selected, and 'Enter Session ID *' which is empty. Below these is a 'More options' link and a blue 'Attend' button. A small question mark icon is also visible.

Choose Language
Click Attend

Step 3



Read Captions on Device
Use Headset for Audio

PID Life Odyssey – The Patient Journey

Moderators:

Dr Nizar Mahlaoui (IPOPI MAP Chair)

Prof Martin Van Hagen (IPOPI Vice-Chair)



IPOPI
5TH REGIONAL
ASIAN PID MEETING
24-25 MARCH 2024
TOKYO, JAPAN
an **IPOPI** event

COLLABORATION



SUPPORTED BY



IPOPI's Global Initiatives for PID Patients

Ms Martine Pergent
IPOPI President



IPOPI
5TH REGIONAL
ASIAN PID MEETING
24-25 MARCH 2024
TOKYO, JAPAN
an **IPOPI** event

COLLABORATION



SUPPORTED BY





What is IPOPI?


- a **non-profit international** organization
- the **leading advocate** for primary immunodeficiency (PID) patients worldwide
- working in **collaboration** with patients, doctors, politicians, regulators, pharmaceutical industry and other relevant stakeholders.

Our mission

To improve awareness, access to early diagnosis and optimal treatments for primary immunodeficiency patients worldwide through global collaboration.



Our members: 73 national patient organisations



Latest countries:

- Algeria
- Bangladesh
- Nepal

Zoom on the Asian region



IPOPI works as an umbrella organisation

A vibrant global
community





A committed Board of Directors

- **Martine Pergent, Chair (FR)**
- **Bruce Lim, Vice-Chair (MAL)**
- Otilia Stanga, Treasurer (RO)
- Roberta Anido de Pena (ARG)
- Whitney Ayoub Goulstone (CA)
- Jose Drabwell (NL/UK)
- Cynthia Olotch (KEN)
- John Seymour (USA)
- Otilia Stanga (RO)
- Johan Prévot (BEL) ex-officio
- Nizar Mahlaoui (FR) ex-officio
- Martin van Hagen (NL) ex-officio

IPOPI dynamic Staff



Executive Director
Johan Prevot

johan@ipopi.org



Events & Logistics Assistant
Alicia Bartos

alicia@ipopi.org



Communications Assistant
Patricia Boldescu

patricia@ipopi.org



Medical Affairs Project Manager
Samya Van Coillie

samya@ipopi.org



Accounting and Administration Manager
Marc Desmet

marc@ipopi.org



NMO Programmes Officer
Miriam Ferreira

miriam@ipopi.org



Financial Advisor
Clare Glynn

clare@ipopi.org



Communications Manager
Rafael Graça

rafael@ipopi.org



Office Manager
Carla Morgado

carla@ipopi.org



Events and Logistics Coordinator
Mercedes Muraca

mercedes@ipopi.org



Health Policy and Advocacy Senior Manager
Leire Solis

leire@ipopi.org

IPOPI Medical Advisory Panel (MAP)



Dr Nizar Mahlaoui,
Chairman (FR)



Prof Martin van Hagen,
Vice-Chair (NL)



IPOPI LeBien AWARD

- **Dr Adli Ali (MAL)**
- Dr Tadej Avcin (Slovenia)
- Prof Aziz Bousfiha (Morocco)
- Dr Charlotte Cunningham-Rundles (USA)
- Dr Virgil Dalm (Netherlands)
- Prof Tandakha Dieye (Senegal)
- Prof Alain Fischer (France)
- Prof Elie Haddad (Canada)
- Professor Steven Holland – (USA)
- **Dr Pamela Lee (Hong-Kong)**
- Prof Isabelle Meyts (Belgium)
- Prof Antonio Condino-Neto (Brazil)
- Dr Olaf Neth (Spain)
- Dr Cecilia Poli – (Chile)
- Dr Elizabeth Rivers – (UK)
- Dr Silvia Sanchez-Ramon (Spain)
- Prof Ana Shcherbina (Russia)
- **Prof Surjit Singh (India)**
- **Prof Stuart Tangye (Australia)**
- Prof Klaus Warnatz (Germany)



Improve access to early
diagnosis & patient-centred care

an IPOPI event

IPOPI

activities & projects



Build capacity and support IPOPI's
national member organisations



Educate, promote knowledge
and data sharing



Strengthen multi-stakeholder
collaboration

Improve access to early diagnosis and patient centred care

Strategic objective 1

COLLABORATION



SUPPORTED BY



Newborn screening for SCIDs



“Neonatal screening is much more than just a simple test.”



screen4rare

What is NBS? MEP Interest Group Resources and other activities About Us

CONTACT

What is NBS?

Home / What is NBS

What is newborn screening?

WHAT DOES NEONATAL SCREENING MEAN FOR PATIENTS?

Timely access to diagnosis, treatment and care!



Global advocacy – Calling for more plasma collection

SAFE Task Force releases two position statements

KEY PUBLICATIONS, NEWS

The Supply and Access for Everyone (SAFE) Task Force and IPOPI position statements on 2 key topics of relevance to patients with



Patients with PID need sustained access to their Ig therapies

Primary immunodeficiencies (or PIDs) are chronic and rare disorders where components of the immune system do not work properly or not at all. Patients need immunoglobulin replacement therapies (Igs) throughout their lives to maintain antibodies within a “suitable” threshold to fight life-impairing or life-threatening infections if alternative treatments are available for these patients.

Igs are plasma-derived medicinal products (PDMPs) that require plasma either through plasmapheresis (source plasma) or from pooled plasma for the development of these medicines

¹.

Each Ig is a unique biological medicine. The different manufacturing processes affect individual patients' tolerability to a given therapy².

Igs are not generic medicines and cannot be interchanged.



Managing demand for immunoglobulins: PIDs are a priority indication at all times

The global demand for immunoglobulin (Ig) replacement therapies is growing annually at 6–8% across a broad range of indications. Whilst strategies to manage Igs demand are urgently needed and should be swiftly implemented in all countries, the fact remains that some countries are still struggling to get access to Ig therapies. Ensuring appropriate, equitable and stable access to Igs in all countries require both increased plasma supply with much more regionally balanced plasma collection and improved fractionation technology to optimize yield from each litre of plasma⁴.


Igs are plasma derived medicinal products (PDMPs) used in the treatment of several diseases and conditions.

Around 60% of patients with primary immunodeficiencies (PIDs) need Igs throughout their lives to keep the levels of antibodies within a “suitable” threshold to fight infections and prevent mortality.

No alternative treatments are available for patients with PIDs requiring Ig therapies¹.

Awareness Campaigns

Universal Health Coverage
Vaccination, ...



Plasma collection
IG availability




Lack of access to UHC is a global problem.

Let's tackle it together.

Join us on Universal Health Coverage Day to make healthcare a universal right.

Antimicrobial resistance



Advocacy World Health Organisation



IGs included in the WHO list of essential medicines

PIDs diagnostic tests included in the WHO Model List of Essential In vitro Diagnostics

Addressing PID patients needs

bringing the patient perspectives on medicines, shortages, clinical trials, ...

- at EMA (European medicine Agency)
- at APEC
(Blood Policy Forums and APEC Rare Disease Forums)
- at Asia Pacific Plasma Leaders Network (APPLN)
- hopefully at AMA (African medicine Agency)



EDUCATION

EVENTS

RESOURCES

LECTURE CATALOG

PRINT CERTIFICATE

UNMET NEED FOR PLASMA DERIVED MEDICINAL PRODUCTS IN APAC: THE PID PATIENT'S PERSPECTIVE

PUBLICATION DATE: 13 October 2023

CONTINUING EDUCATION UNITS: 0.5 hours

LECTURE DESCRIPTION:

In this lecture, Johan Prevot, Executive Director of the International Patient Organisation for Primary Immunodeficiencies (IPOPI), describes the organization and provides an overview of the evolving use of immunoglobulins. His presentation

Have PIDs on the political agendas



Meetings at the European parliament chaired by members of Parliament on diverse topics

- Digital health
- Collection of plasma, supply of IGs
- Cross border care

At the Brazilian Parliament



Build capacity and support IPOPI's National Member organisations

Strategic objective 2

COLLABORATION



SUPPORTED BY



Patient community momentum

Global Patients Meeting

- Biennial meeting open for all NMOs, organised in parallel to ESID & INGID congresses
- Next meeting in Marseille (France), October 2024
- 2-day meeting with educational sessions, skills building workshops and exchange of experiences
- Hosts the PID Champions Awards

Regional PID meetings

- Regional meeting open for all NMOs from the region, organised in parallel to regional scientific societies (ASID, LASID, APSID/SEA) & INGID congresses

Webchats

- Community online regular meetings



Help our members take action



COVID-19 and PIDs FAQs

Updated April 29, 2020

This is a compilation of answers to questions received from IPOPI's national member organisations via email, social media and during IPOPI's COVID-19 webchats.

New statement: A PID causing a heavy burden of disease must always be recognised as a disability



Training sessions with play roles


In Asia



In Africa

4ID app.

- A health calendar ...
A source of information
when you visit your
specialist
- A Source a patients'
real-life data



World Primary Immunodeficiencies Week 22-29 April every year

すべての原発性免疫不全患者に対するケアへのアクセス、どこでも

Let's make early diagnosis & timely access to quality treatment a reality worldwide

#WorldPIWeek




World PI Week
TEST • DIAGNOSE • TREAT

2024 年 4 月
22 ~ 29 日

Educate, promote knowledge & data sharing

Strategic objective 3

COLLABORATION



SUPPORTED BY



Educational material


Leaflets
Webinars

- For health care professionals



Educational material

- For patients
- For the general public



Primary immunodeficiency

A guide for schools



Mini-documentary



INVITATION



an IPOPl event

IPIC2025

INTERNATIONAL
PRIMARY
IMMUNODEFICIENCIES
CONGRESS

DIAGNOSIS
AND CLINICAL CARE

PRAGUE, CZECH REPUBLIC
5-7 NOVEMBER 2025

ipic2025.com

PIDetect: Training programme

Indonesia > Erasmus, Rotterdam

Bangladesh > PGIMER Chandigarh, India

Moldova > Timisoara, Romania



IPOPI Latest Publications

Solis et al. *Orphanet Journal of Rare Diseases* (2022) 17:11
<https://doi.org/10.1186/s13023-021-02161-0>

Orphanet Journal of Rare Diseases

RESEARCH Open Access

The PID Life Index: an interactive tool to measure the status of the PID healthcare environment in any given country

Leire Solís¹, Julia Nordin¹, Johan Prevot¹, Nizar Mahlaoui^{2,3}, Silvia Sánchez-Ramón^{4,5}, Adli Ali^{6,7}, Elodie Cassignol⁸, John W. Seymour^{1,9} and Martine Pergent^{1*}

Abstract

Background: The 'Primary Immunodeficiencies (PIDs) principles of care' were published in 2014 as the gold standard for care of patients with PIDs, setting a common goal for stakeholders to ensure that patients with PID have appropriate care and good quality of life. Since then, IPOPI (the International Patient Organisation for Primary Immunodeficiencies), has been working with national PID patient organisations as well as collaborating with scientific medical institutions and experts to bring these principles closer to the day-to-day life of individuals with PID.

Method: The six PID Principles of Care were revised to consider advances in the field, as well as political developments that had occurred after their initial publication in 2014. Based on this revision the list was updated, an principle was added. The six established principles were: diagnosis, treatment, universal health coverage, special centres, national patient organisations and registries. Each principle was structured and measured through a criteria, and was given the same weight, as they have been considered to all be equally important. Specific criteria were attributed to the criteria depending on their relevance and importance to quantify the principle. The criteria were translated into a survey for data collection: initially involving data from selected countries for a pilot, followed by a nationwide survey of data from IPOPI's national member organisations and key countries.

Results: The PID Life Index was developed in 2020 to assess the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

Conclusion: The PID Life Index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

Orphanet Journal of Rare Diseases

RESEARCH Open Access

Global immunoglobulin supply: steaming towards the iceberg?

Johan Prevot^a and Stephen Jolles^b

Abstract

Background: The 'Primary Immunodeficiencies (PIDs) principles of care' were published in 2014 as the gold standard for care of patients with PIDs, setting a common goal for stakeholders to ensure that patients with PID have appropriate care and good quality of life. Since then, IPOPI (the International Patient Organisation for Primary Immunodeficiencies), has been working with national PID patient organisations as well as collaborating with scientific medical institutions and experts to bring these principles closer to the day-to-day life of individuals with PID.

Method: The six PID Principles of Care were revised to consider advances in the field, as well as political developments that had occurred after their initial publication in 2014. Based on this revision the list was updated, an principle was added. The six established principles were: diagnosis, treatment, universal health coverage, special centres, national patient organisations and registries. Each principle was structured and measured through a criteria, and was given the same weight, as they have been considered to all be equally important. Specific criteria were attributed to the criteria depending on their relevance and importance to quantify the principle. The criteria were translated into a survey for data collection: initially involving data from selected countries for a pilot, followed by a nationwide survey of data from IPOPI's national member organisations and key countries.

Results: The PID Life Index was developed in 2020 to assess the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

Conclusion: The PID Life Index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

The Lancet Regional Health - Europe
2022;00: 100311
Published online xxx
<https://doi.org/10.1016/j.lanepe.2022.100311>

Newborn screening as a fully integrated system to stimulate equity in neonatal screening in Europe

Maurizio Scarpa^{a,*}, James R. Bonham^b, Carlo Dionisi-Vici^c, Johan Prevot^d, Martine Pergent^d, Isabelle Meyts^e, Nizar Mahlaoui^f, and Peter C.J.J. Schielen^g

Abstract

Background: The 'Primary Immunodeficiencies (PIDs) principles of care' were published in 2014 as the gold standard for care of patients with PIDs, setting a common goal for stakeholders to ensure that patients with PID have appropriate care and good quality of life. Since then, IPOPI (the International Patient Organisation for Primary Immunodeficiencies), has been working with national PID patient organisations as well as collaborating with scientific medical institutions and experts to bring these principles closer to the day-to-day life of individuals with PID.

Method: The six PID Principles of Care were revised to consider advances in the field, as well as political developments that had occurred after their initial publication in 2014. Based on this revision the list was updated, an principle was added. The six established principles were: diagnosis, treatment, universal health coverage, special centres, national patient organisations and registries. Each principle was structured and measured through a criteria, and was given the same weight, as they have been considered to all be equally important. Specific criteria were attributed to the criteria depending on their relevance and importance to quantify the principle. The criteria were translated into a survey for data collection: initially involving data from selected countries for a pilot, followed by a nationwide survey of data from IPOPI's national member organisations and key countries.

Results: The PID Life Index was developed in 2020 to assess the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

Conclusion: The PID Life Index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

frontiers | Frontiers in Immunology

TYPE Original Research
PUBLISHED 30 March 2023
DOI 10.3389/fimmu.2023.1151355

Primary immunodeficiencies (PID) Life Index in Southeast Asia: A comparative analysis of PID Principles of Care (PoC)

Chee Mun Chan^{1,2}, Nizar Mahlaoui^{3,4}, Silvia Sánchez-Ramón^{5,6}, Martine Pergent⁷, Leire Solís⁸, Johan Prevot⁹ and Adli Ali^{1,2,8,9*}

Abstract

Background: The 'Primary Immunodeficiencies (PIDs) principles of care' were published in 2014 as the gold standard for care of patients with PIDs, setting a common goal for stakeholders to ensure that patients with PID have appropriate care and good quality of life. Since then, IPOPI (the International Patient Organisation for Primary Immunodeficiencies), has been working with national PID patient organisations as well as collaborating with scientific medical institutions and experts to bring these principles closer to the day-to-day life of individuals with PID.

Method: The six PID Principles of Care were revised to consider advances in the field, as well as political developments that had occurred after their initial publication in 2014. Based on this revision the list was updated, an principle was added. The six established principles were: diagnosis, treatment, universal health coverage, special centres, national patient organisations and registries. Each principle was structured and measured through a criteria, and was given the same weight, as they have been considered to all be equally important. Specific criteria were attributed to the criteria depending on their relevance and importance to quantify the principle. The criteria were translated into a survey for data collection: initially involving data from selected countries for a pilot, followed by a nationwide survey of data from IPOPI's national member organisations and key countries.

Results: The PID Life Index was developed in 2020 to assess the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

Conclusion: The PID Life Index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

International Journal of Neonatal Screening

REVIEW

Towards Achieving Equity and Innovation in Newborn Screening across Europe

Jaka Sikonia^{1,2,*}, Uth Groselj^{1,2,*}, Maurizio Scarpa³, Giancarlo la Marca^{4,5}, David Cheillan^{6,7}, Stefan Köllker⁷, Rolf H. Zetterström^{8,9}, Viktor Kožich^{10,11}, Yann Le Cam¹², Gulcin Gunus¹², Valentina Bottarelli¹², Mirjam van der Burg¹³, Eugénie Dekkers¹⁴, Tadej Battelino^{1,2}, Johan Prevot¹⁵, Peter C. J. I. Schielen¹⁶ and James R. Bonham^{16,17,*}

Abstract

Background: The 'Primary Immunodeficiencies (PIDs) principles of care' were published in 2014 as the gold standard for care of patients with PIDs, setting a common goal for stakeholders to ensure that patients with PID have appropriate care and good quality of life. Since then, IPOPI (the International Patient Organisation for Primary Immunodeficiencies), has been working with national PID patient organisations as well as collaborating with scientific medical institutions and experts to bring these principles closer to the day-to-day life of individuals with PID.

Method: The six PID Principles of Care were revised to consider advances in the field, as well as political developments that had occurred after their initial publication in 2014. Based on this revision the list was updated, an principle was added. The six established principles were: diagnosis, treatment, universal health coverage, special centres, national patient organisations and registries. Each principle was structured and measured through a criteria, and was given the same weight, as they have been considered to all be equally important. Specific criteria were attributed to the criteria depending on their relevance and importance to quantify the principle. The criteria were translated into a survey for data collection: initially involving data from selected countries for a pilot, followed by a nationwide survey of data from IPOPI's national member organisations and key countries.

Results: The PID Life Index was developed in 2020 to assess the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

Conclusion: The PID Life Index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

Qualitative Research in Medicine & Healthcare 2020; volume 4:117-131

It's long-term, well it's for life basically: Understanding and exploring the burden of immunoglobulin treatment in patients with primary immunodeficiency disorders

Georgina I. Jones¹, Eva Brown Hajdukova², Esme Hanna³, Rosie Duncan⁴, Brendan Gough¹, Jane Hughes⁴, Debbie Hughes⁵, Fran Ashworth⁵, Johan Prevot⁶, Jose Drabwell⁷, Leire Solís⁸, Nizar Mahlaoui⁹, Anna Shrimpton⁹ on behalf of the International IgBoT study team

Abstract

Background: The 'Primary Immunodeficiencies (PIDs) principles of care' were published in 2014 as the gold standard for care of patients with PIDs, setting a common goal for stakeholders to ensure that patients with PID have appropriate care and good quality of life. Since then, IPOPI (the International Patient Organisation for Primary Immunodeficiencies), has been working with national PID patient organisations as well as collaborating with scientific medical institutions and experts to bring these principles closer to the day-to-day life of individuals with PID.

Method: The six PID Principles of Care were revised to consider advances in the field, as well as political developments that had occurred after their initial publication in 2014. Based on this revision the list was updated, an principle was added. The six established principles were: diagnosis, treatment, universal health coverage, special centres, national patient organisations and registries. Each principle was structured and measured through a criteria, and was given the same weight, as they have been considered to all be equally important. Specific criteria were attributed to the criteria depending on their relevance and importance to quantify the principle. The criteria were translated into a survey for data collection: initially involving data from selected countries for a pilot, followed by a nationwide survey of data from IPOPI's national member organisations and key countries.

Results: The PID Life Index was developed in 2020 to assess the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

Conclusion: The PID Life Index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

frontiers | Frontiers in Immunology

TYPE Original Research
PUBLISHED 18 April 2023
DOI 10.3389/fimmu.2023.1166198

COVID-19 vaccination in patients with primary immunodeficiencies: an international survey on patient vaccine hesitancy and self-reported adverse events

Martine Pergent^{1*}, Filomee Haerynck^{2,3}, Levi Hoste^{2,3} and Ann Gardulf^{4,5,6}

Abstract

Background: The 'Primary Immunodeficiencies (PIDs) principles of care' were published in 2014 as the gold standard for care of patients with PIDs, setting a common goal for stakeholders to ensure that patients with PID have appropriate care and good quality of life. Since then, IPOPI (the International Patient Organisation for Primary Immunodeficiencies), has been working with national PID patient organisations as well as collaborating with scientific medical institutions and experts to bring these principles closer to the day-to-day life of individuals with PID.

Method: The six PID Principles of Care were revised to consider advances in the field, as well as political developments that had occurred after their initial publication in 2014. Based on this revision the list was updated, an principle was added. The six established principles were: diagnosis, treatment, universal health coverage, special centres, national patient organisations and registries. Each principle was structured and measured through a criteria, and was given the same weight, as they have been considered to all be equally important. Specific criteria were attributed to the criteria depending on their relevance and importance to quantify the principle. The criteria were translated into a survey for data collection: initially involving data from selected countries for a pilot, followed by a nationwide survey of data from IPOPI's national member organisations and key countries.

Results: The PID Life Index was developed in 2020 to assess the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

Conclusion: The PID Life Index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

frontiers | Frontiers in Immunology

TYPE Original Research
PUBLISHED 30 March 2023
DOI 10.3389/fimmu.2023.1151355

Primary immunodeficiencies (PID) Life Index in Southeast Asia: A comparative analysis of PID Principles of Care (PoC)

Chee Mun Chan^{1,2}, Nizar Mahlaoui^{3,4}, Silvia Sánchez-Ramón^{5,6}, Martine Pergent⁷, Leire Solís⁸, Johan Prevot⁹ and Adli Ali^{1,2,8,9*}

Abstract

Background: The 'Primary Immunodeficiencies (PIDs) principles of care' were published in 2014 as the gold standard for care of patients with PIDs, setting a common goal for stakeholders to ensure that patients with PID have appropriate care and good quality of life. Since then, IPOPI (the International Patient Organisation for Primary Immunodeficiencies), has been working with national PID patient organisations as well as collaborating with scientific medical institutions and experts to bring these principles closer to the day-to-day life of individuals with PID.

Method: The six PID Principles of Care were revised to consider advances in the field, as well as political developments that had occurred after their initial publication in 2014. Based on this revision the list was updated, an principle was added. The six established principles were: diagnosis, treatment, universal health coverage, special centres, national patient organisations and registries. Each principle was structured and measured through a criteria, and was given the same weight, as they have been considered to all be equally important. Specific criteria were attributed to the criteria depending on their relevance and importance to quantify the principle. The criteria were translated into a survey for data collection: initially involving data from selected countries for a pilot, followed by a nationwide survey of data from IPOPI's national member organisations and key countries.



Results: The PID Life Index was developed in 2020 to assess the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

Conclusion: The PID Life Index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care. The index is a tool to measure the status of the PID environment and the implementation of the 6 principles of care.

Data: the PID Life Index


- built on 6 key principles of care
- It measures the status of the PID healthcare environment across the globe

<https://pidlifeindex.ipopi.org>



How's life with a Primary Immunodeficiency (PID)?

The PID Life Index is an interactive tool built on 6 key principles of care that measures the status of the PID healthcare environment in a country.



Strengthen multi-stakeholder collaboration

Strategic objective 4

COLLABORATION



SUPPORTED BY



Red Cross blood collection centres, hospital teams



in Thailand



In Indonesia



Prof Chean Sôphal, Cambodia



Dr Yae-Jean Kim, Korea

Research

IPOPI active in several research programmes:

- Recomb,
- 3D-GATA2
- INTEGRATE-ATMPs
- JAKI consensus



UNITAR SIGNS A MEMORANDUM OF UNDERSTANDING WITH IPOPI



IPOPI


14 August 2023, Geneva, Switzerland - We are pleased to announce that UNITAR, the United Nations Institute for Training and Research, and IPOPI, the International Patient Organization for Primary Immunodeficiencies, have entered into a new Memorandum of Understanding (MoU). This agreement represents a strong commitment to collaborating and cooperating to make a positive impact on access to plasma-derived therapies worldwide.

The MoU enhances our existing collaboration, elevating it to a true partnership. It promotes cooperation through various means, such as knowledge sharing, innovative education, training, capacity-building solutions, and raising awareness to improve access to healthcare in the field of plasma-derived therapies.

Through this collaborative endeavour, UNITAR and IPOPI aim to make significant strides in advancing healthcare and capacity-building initiatives. The partnership's collective efforts will lead to tangible and sustainable impacts, benefitting communities worldwide.

We look forward to embarking on this journey together and remain committed to fostering a meaningful and lasting

Global initiatives with national pilots



Launch of the International Coalition for Safe Plasma Proteins (ICSPP)

Organizations join with ISBT to advance global access to safe plasma proteins



The ISBT Working Party on Global Blood Safety initiated the ICSPP as a global coalition to advance access to safe plasma proteins in Low- and Middle- Income Countries. In cooperation with the World Health Organization, this coalition was established to address the global insufficiency of plasma-derived medicinal products that are unavailable or unaffordable in many low- and middle- income countries (LMIC) and the consequent suffering and early mortality of patients



International Society
of Blood Transfusion



World Health
Organization



WFH

WORLD FEDERATION OF HEMOPHILIA




PLASMA PROTEIN
THERAPEUTICS
ASSOCIATION

Global initiatives with national pilots



Looking towards the future (What's Up in 2030)



OPEN ACCESS

EDITED BY
Frank Staal,
Leiden University Medical Center (LUMC),
Netherlands

REVIEWED BY
Amir Hamzah Abdul Latiff,
Pantai Hospital Kuala Lumpur, Malaysia
Hamoud Al-Mousa,
King Faisal Specialist Hospital and Research
Centre, Saudi Arabia

*CORRESPONDENCE
Nizar Mahlaoui
✉ nizar.mahlaoui@aphp.fr

RECEIVED 23 June 2023
ACCEPTED 24 July 2023
PUBLISHED 15 August 2023

CITATION
Tadros S, Prévot J, Meyts I,
Sánchez-Ramón S, Erwa NH, Fischer A,
Lefevre G, Hotchkiss M, Jaworski PM,
Leavis H, Boersma C, Drabwell J, van
Hagen M, Van Coillie S, Pergent M,
Burns SO and Mahlaoui N (2023) The PID
Odyssey 2030: outlooks, unmet needs,
hurdles, and opportunities — proceedings
from the IPOPI global multi-stakeholders'
summit (June 2022).
Front. Immunol. 14:1245718.
doi: 10.3389/fimmu.2023.1245718

COPYRIGHT
© 2023 Tadros, Prévot, Meyts,
Sánchez-Ramón, Erwa, Fischer, Lefevre,
Hotchkiss, Jaworski, Leavis, Boersma,
Drabwell, van Hagen, Van Coillie, Pergent,
Burns and Mahlaoui. This is an open-access
article distributed under the terms of the
Creative Commons Attribution License
(CC BY). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

The PID Odyssey 2030: outlooks, unmet needs, hurdles, and opportunities — proceedings from the IPOPI global multi-stakeholders' summit (June 2022)

Susan Tadros¹, Johan Prévot², Isabelle Meyts^{3,4},
Silvia Sánchez-Ramón⁵, Nahla H. Erwa⁶, Alain Fischer^{7,8,9,10},
Guillaume Lefevre^{11,12}, Matthew Hotchkiss¹³, Peter M. Jaworski¹⁴,
Helen Leavis¹⁵, Cornelis Boersma^{16,17,18}, Jose Drabwell²,
Martin van Hagen^{19,20}, Samya Van Coillie², Martine Pergent²,
Siobhan O. Burns¹ and Nizar Mahlaoui^{2,7,8*}

¹Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom,
²IPOPI, Brussels, Belgium, ³Department of Pediatrics, University Hospitals Leuven, KU Leuven,
Leuven, Belgium, ⁴Department of Microbiology, Immunology and Transplantation, KU Leuven,
Leuven, Belgium, ⁵Department of Immunology, Health Research Institute of the Hospital Clínico San
Carlos (IdISSC), IML and IdISSC, Madrid, Spain, ⁶Faculty of Medicine, University of Khartoum,
Khartoum, Sudan, ⁷Pediatric Hematology-Immunology and Rheumatology Unit, Necker-Enfants
malades University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁸French
National Reference Center for Primary Immune Deficiencies (CEREDIH), Necker-Enfants malades
University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁹Collège de France,
Paris, France, ¹⁰Imagine Institute, UMR Inserm 1163, Paris, France, ¹¹Univ. Lille, Inserm, CHU Lille,
U1286 – INFINITE Institut de recherche translationnelle sur l'inflammation, Lille, France, ¹²Institut
d'Immunologie, CHU Lille, Lille, France, ¹³Marketing Research Bureau, Inc., Yakima, WA, United States,
¹⁴Strategy, Ethics, Economics, and Public Policy, McDonough School of Business, Georgetown
University, Washington, DC, United States, ¹⁵Department of Rheumatology & Clinical Immunology,
University Medical Center (UMC), Utrecht University, Utrecht, Netherlands, ¹⁶Health-Ecore B.V.,
Zeist, Netherlands, ¹⁷Unit of Global Health, Department of Health Sciences, University Medical Center
Groningen (UMCG), University of Groningen, Groningen, Netherlands, ¹⁸Department of Management
Sciences, Open University, Heerlen, Netherlands, ¹⁹Department of Internal Medicine, Division of Allergy
& Clinical Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands,
²⁰Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands

IPOPI held its first Global Multi-Stakeholders' Summit on 23-24 June 2022 in
Cascais, Portugal. This IPOPI initiative aims to bring together experts from various fields to discuss the latest research and clinical practice in PID and to develop a vision for the future of the field.

In the pipes...

COLLABORATION



SUPPORTED BY



In the pipes

The SIDE Project: Secondary ImmunoDeficiency

- to assess whether specific subsets of SID patients could be represented by IPOPI

AI Rare

- Exploring the potential of artificial intelligence

IPOPI Research Grants

- to promote scientific and clinical research in the field of immunodeficiencies.

IPOPI Collaborative Centres

- Expert centres will be recognized for their commitment to a patient-centred collaborative approach in accordance with the values and principles upheld by IPOPI.

Thank you for your kind attention!

Thank you to
our sponsors
for making this
important
meeting
possible

どうもありがとう

매우 감사합니다

太感谢了

धेरै धेरै धन्यवाद

Terima kasih banyak-banyak

आपका बहुत-बहुत धन्यवाद

ကျေးဇူးတင်ပါသည်

Cảm ơn bạn rất nhiều

তোমাকে অনেক ধন্যবাদ

COLLABORATION



SUPPORTED BY



Issues in Transitional and Adult Care of PID Patients in Japan

Ms Tomoko Kaito
PID Tsubasa-no-Kai, Japan.



IPOPI
5TH REGIONAL
ASIAN PID MEETING
24-25 MARCH 2024
TOKYO, JAPAN
an IPOPI event

COLLABORATION



SUPPORTED BY



Issue on Transitional Care of PID patients in Japan

Tomoko Kaito
PID Tsubasa no kai



March 24, 2024

Activities of PID Tsubasa no kai



Coordination of interactions among members

- Exchange information and opinions on each disease type and theme at online member exchange meetings



Holding medical lectures (once a year)

- “Reversion of genetic mutation in PID –natural gene therapy- ” by Prof. Wada of Kanazawa University Dec 10, 2023



Medical consultation Sessions (twice a year)

- Medical advisors answer to medical consultations received from members



Disseminating the latest medical-related information through newsletters and e-mails

- Ex: Information on vaccines and neutralizing antibody drugs for COVID-19

Activities of PID Tsubasa no kai



Cooperation in the expansion and promotion of PID newborn mass screening

- Visited to legislators to request the implementation of expanded newborn mass screening nationwide at public expense. Submitted written request



Activities to spread awareness about PID

- Awareness promotion activities in conjunction with World PI Week
- Information dissemination through SNS/website



Respond to PID inquiries from members/non-members


- Answer to specialized questions after consulting with medical advisors.
- Answer to patients concerns by board members and other patient family members





Activities for physical disability certification

- Dedicated team launched to obtain physical disability certificate

Clinical pattern of the members



Age at diagnosis



Issues on transitional care and adult medical treatment

- Difficulties in transitioning from pediatrics to adult medicine
- Cannot find a specialist who can treat adult patients
- Difficulty of cooperation between neighboring hospitals and PID specialists

Ideal structure in adult medical treatment



PID specialist

Doctors who understand PID

- Providing treatment guidelines
- Follow-up with periodic visits



Cooperation

**Other departments
in the hospital**

Cooperation

Neighborhood clinics/Family doctors



- Dealing with daily problems (fever, cold, etc.)
- Prescribing regular medications in collaboration with PID specialists (prophylaxis, globulin products, etc.)
- Prescribing drugs that are only prescribed on a monthly basis

Otolaryngology,
ophthalmology,
odontology,
dermatology, etc.



Difficulties in transitional care and adult medical treatment

In case of transition from child to adult

from pediatric specialist



to internist



Difficult to find internist with knowledge of PID

In case of not diagnosed in childhood

Much more severe than transition care



Difficult to find a doctor who can diagnose PID



Summary

Few internists are able to see adult patients with PID, which often makes finding an appropriate doctor difficult. This is especially difficult in cases where the diagnosis is made later in life.

For adult patients,

- A system in which a pediatric specialist first examines the patient and then links the patient to an internist.
- Medical institutions that serve as centers where PID can be diagnosed and treated

would lead to early diagnosis and appropriate treatment initiation for these patients (or potential patients).

With the decision to implement a publicly funded policy of mass screening of newborns in Japan, it is expected that the number of patients diagnosed with PID will increase in the future. We expect that resolving issues now will lead to solutions more than a decade from now.

We ask for your help in establishing cooperative medical care that can provide peace of mind to patients at any age.

Thank you for your attention!

Panel discussion on the PID Life Odyssey The Patient Journey

Ms Martine Pergent (IPOPI President),
Mr Bruce Lim (IPOPI Vice-President),
Mr Shun Kimura (PID Tsubasa-no-Kai)



IPOPI
5TH REGIONAL
ASIAN PID MEETING
24-25 MARCH 2024
TOKYO, JAPAN
an **IPOPI** event

COLLABORATION



SUPPORTED BY



THANK YOU FOR PARTICIPATING!

To further enhance the quality of our meetings, we kindly request a few moments of your valuable time to provide your feedback.

Please scan the QR Code:



COLLABORATION



SUPPORTED BY



Thank you!



IPOPI
5TH REGIONAL
ASIAN PID MEETING
24-25 MARCH 2024
TOKYO, JAPAN
an **IPOPI** event

COLLABORATION



SUPPORTED BY



IPOPI.ORG